The Synergistic Effect of Baloxavir and Neuraminidase Inhibitors against Influenza Viruses In Vitro
Viruses · 2024
DOI: 10.3390/v16091467 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, 2024. Verfasst von Xiaojia Guo und 4 weiteren Autor:innen. Beteiligte Einrichtung: National Engineering Research Center for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China. Hauptthemen laut MEDLINE: Dibenzothiepins, Antiviral Agents, Triazines, Drug Synergism. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the National Natural Science Foundation of China, National Natural Science Foundation of China, National Science and Technology Major Projects “Major New Drugs Innovation and Development”.
Abstract (Originalsprache)
Influenza viruses remain a major threat to human health. Four classes of drugs have been approved for the prevention and treatment of influenza infections. Oseltamivir, a neuraminidase inhibitor, is a first-line anti-influenza drug, and baloxavir is part of the newest generation of anti-influenza drugs that targets the viral polymerase. The emergence of drug resistance has reduced the efficacy of established antiviral drugs. Combination therapy is one of the options for controlling drug resistance and enhancing therapeutical efficacies. Here, we evaluate the antiviral effects of baloxavir combined with neuraminidase inhibitors (NAIs) against wild-type influenza viruses, as well as influenza viruses with drug-resistance mutations. The combination of baloxavir with NAIs led to significant synergistic effects; however, the combination of baloxavir with laninamivir failed to result in a synergistic effect on influenza B viruses. Considering the rapid emergence of drug resistance to baloxavir, we believe that these results will be beneficial for combined drug use against influenza.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Engineering Research Center for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China.
- Beijing Sunho Pharmaceutical Co., Ltd., Beijing 102600, China.
ORCID-Profile: Wu Zhong
Förderung
- the National Natural Science Foundation of China
- National Natural Science Foundation of China
- National Science and Technology Major Projects “Major New Drugs Innovation and Development”
Zitieren
APA
Guo, X., Zhao, L., Li, W., Cao, R., & Zhong, W. (2024). The Synergistic Effect of Baloxavir and Neuraminidase Inhibitors against Influenza Viruses In Vitro. Viruses. https://doi.org/10.3390/v16091467
Vancouver
Guo X, Zhao L, Li W, Cao R, Zhong W. The Synergistic Effect of Baloxavir and Neuraminidase Inhibitors against Influenza Viruses In Vitro. Viruses. 2024. doi:10.3390/v16091467
BibTeX
@article{Guo2024,
author = {Guo, Xiaojia and Zhao, Lei and Li, Wei and Cao, Ruiyuan and Zhong, Wu},
title = {The Synergistic Effect of Baloxavir and Neuraminidase Inhibitors against Influenza Viruses In Vitro},
journal = {Viruses},
year = {2024},
doi = {10.3390/v16091467}
}
EUVIMED